Digital memory assessments and plasma pTau217 enable efficient preclinical Alzheimer’s trials
A brief DMA combined with plasma pTau217 identifies a subset of cognitively unimpaired, amyloid-positive older adults at highest risk for cognitive and biomarker progression. This dual-marker enrichment strategy enables smaller, shorter, and more cost-efficient preclinical AD trials and supports more targeted evaluation of preventive therapies.
Authors
- Casey R. Vanderlip (ORCID: https://orcid.org/0000-0002-8233-5829)
- Craig E.L. Stark
- Joshua D. Grill
- Daniel L. Gillen
Institutions
- University of California, Irvine (US)
- Irvine University (US)
Publication Details
- Journal
- The Journal of Prevention of Alzheimer s Disease
- Published
- 2026-02-06
- DOI
- https://doi.org/10.1016/j.tjpad.2026.100503
- Citations
- 1
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 33.12